PT732928E - Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois - Google Patents

Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois

Info

Publication number
PT732928E
PT732928E PT95901141T PT95901141T PT732928E PT 732928 E PT732928 E PT 732928E PT 95901141 T PT95901141 T PT 95901141T PT 95901141 T PT95901141 T PT 95901141T PT 732928 E PT732928 E PT 732928E
Authority
PT
Portugal
Prior art keywords
silyphenois
dialquil
cholesterol levels
serum cholesterol
reducing serum
Prior art date
Application number
PT95901141T
Other languages
English (en)
Inventor
Roger A Parker
Simon J T Mao
Mark T Yates
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of PT732928E publication Critical patent/PT732928E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
PT95901141T 1993-12-10 1994-11-03 Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois PT732928E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528193A 1993-12-10 1993-12-10

Publications (1)

Publication Number Publication Date
PT732928E true PT732928E (pt) 2005-03-31

Family

ID=22598245

Family Applications (2)

Application Number Title Priority Date Filing Date
PT95901141T PT732928E (pt) 1993-12-10 1994-11-03 Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois
PT04016883T PT1468692E (pt) 1993-12-10 1994-11-03 Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04016883T PT1468692E (pt) 1993-12-10 1994-11-03 Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma

Country Status (16)

Country Link
EP (3) EP0732928B1 (pt)
JP (1) JPH09511222A (pt)
CN (1) CN1092517C (pt)
AT (2) ATE324113T1 (pt)
AU (1) AU681731B2 (pt)
CA (1) CA2177968C (pt)
DE (2) DE69434198T2 (pt)
DK (2) DK1468692T3 (pt)
ES (2) ES2263094T3 (pt)
HU (1) HU220761B1 (pt)
IL (1) IL111905A (pt)
NO (1) NO311868B1 (pt)
NZ (1) NZ276285A (pt)
PT (2) PT732928E (pt)
WO (1) WO1995015760A1 (pt)
ZA (1) ZA949663B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EA009987B1 (ru) * 1997-05-14 2008-04-28 Атеродженикс, Инк. Производные пробукола для лечения заболеваний, опосредованных vcam-1
NZ501342A (en) * 1997-06-24 2001-10-26 Aventis Pharma Inc Alkyl-4-silyl(furanyl or thienyl) phenols as antioxidant agents
EP0996623A1 (en) * 1997-06-25 2000-05-03 Hoechst Marion Roussel, Inc. 2,6-DI-t-BUTYL-4- (DIMETHYL-4-METHOXYPHENYLSILYL) -METHYLOXY]PHENOL AND 2,6-DI-t-BUTYL-4- (DIMETHYL-2-METHOXY-PHENYLSILYL) -METHYLOXY]PHENOL
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
EA200000087A1 (ru) 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
MXPA01004683A (es) * 1998-11-09 2002-09-18 Atherogenics Inc Metodos y composiciones para disminuir los niveles de colesterol en el plasma.
US6821738B2 (en) 1999-01-20 2004-11-23 The Board Of Regents For Oklahoma State University Broad spectrum bio-detection of nerve agents, organophosphates, and other chemical warfare agents
US6545007B2 (en) 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US6960683B2 (en) 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
WO2004108094A2 (en) 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005039596A1 (en) * 2003-10-17 2005-05-06 Amylin Pharmaceuticals, Inc. Silyl phenols for promoting vascular health
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE349046B (pt) * 1966-12-23 1972-09-18 C Guevne
FR2230376A1 (en) * 1973-05-24 1974-12-20 Gueyne Jean Stable solutions of siloxanic polysilanols - prepd. by hydrolysis of a silane and having pharmaceutical activity
FR2308372A2 (fr) * 1975-04-21 1976-11-19 Cortial Produits pharmaceutiques contenant un compose organosilicie en tant qu'agent actif
US4670421A (en) * 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
NZ238807A (en) * 1990-07-05 1994-03-25 Merrell Dow Pharma Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents

Also Published As

Publication number Publication date
CA2177968A1 (en) 1995-06-15
HU9601590D0 (en) 1996-08-28
IL111905A (en) 2001-04-30
DE69434198D1 (de) 2005-01-27
ZA949663B (en) 1995-08-15
HUT74015A (en) 1996-10-28
PT1468692E (pt) 2006-09-29
ATE324113T1 (de) 2006-05-15
IL111905A0 (en) 1995-03-15
WO1995015760A1 (en) 1995-06-15
DK1468692T3 (da) 2006-08-28
EP0732928A1 (en) 1996-09-25
CN1092517C (zh) 2002-10-16
NZ276285A (en) 2004-11-26
AU681731B2 (en) 1997-09-04
ES2263094T3 (es) 2006-12-01
EP1468692A3 (en) 2004-11-03
CA2177968C (en) 2000-03-28
ATE285238T1 (de) 2005-01-15
DE69434198T2 (de) 2005-12-29
HU220761B1 (hu) 2002-05-28
EP1468693A3 (en) 2004-11-03
NO311868B1 (no) 2002-02-11
AU1049995A (en) 1995-06-27
DE69434720D1 (de) 2006-06-01
EP1468693A2 (en) 2004-10-20
DK0732928T3 (da) 2005-04-18
EP0732928B1 (en) 2004-12-22
EP1468692B1 (en) 2006-04-26
ES2233937T3 (es) 2005-06-16
DE69434720T2 (de) 2007-05-16
EP1468692A2 (en) 2004-10-20
CN1140995A (zh) 1997-01-22
NO962415L (no) 1996-06-07
JPH09511222A (ja) 1997-11-11
NO962415D0 (no) 1996-06-07

Similar Documents

Publication Publication Date Title
PT732928E (pt) Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois
CA2046051A1 (en) 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
NO179142C (no) 3-benzyliden-1-karbamoyl-2-pyrrolidon-analoger
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
BR1101017A (pt) Distamicina a análoga; processo para a apresentação de um composto; composição farmacêutica contendo um composto; e uso de um composto
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
PT98362A (pt) Processo para a preparacao de derivados de tioalquiltio-cefalosporina e de composicoes farmaceuticas que os contem
FI882477A0 (fi) >nya alkansulfonanilidderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
ES2140393T3 (es) Compuestos de penem.
AU703092B2 (en) Benzene derivatives
NO960308L (no) Terapeutisk aktive benzoksaziner og benzotioanoner
ATE156487T1 (de) Mercapto-acetamid-derivate
ATE143591T1 (de) Verwendung von bis-(p- hydroxyphenylthio)methanderivaten zur hemmung der fortschreitenden entwicklung von insulinabhängingem diabetes mellitus
DK0532725T3 (da) Isoxazolderivater som lysfilterpræparater
AU8292787A (en) Fluorine-containing macrolide compounds and their use